Lindsey Draper, MD
Adjunct Instructor
Medicine
School of Medicine

Dr. Lindsey Draper is an Adjunct Instructor in the Department of Medicine at the University of California, San Francisco, where she specializes in the care of patients with ovarian cancer. As a physician-scientist in the Roybal Laboratory, she conducts research at the intersection of immunology and synthetic biology to develop novel immunotherapies for patients with ovarian cancer and other aggressive solid tumors.

Show full bio (100 words) Hide full bio

Her work focuses on genetically enhancing tumor-infiltrating lymphocytes (TILs) to overcome mechanisms of resistance in ovarian cancer, with the goal of creating safer and more effective treatment options.

Dr. Draper brings extensive expertise in immunotherapy, including her prior work in the laboratory of Dr. Steven A. Rosenberg at the National Cancer Institute, where she contributed to efforts in TIL therapy and T-cell receptor discovery for HPV-associated cancers. This work led to multiple clinical trials that, for the first time, demonstrated that cellular therapeutics can induce responses in patients with epithelial malignancies.

Awards

Show all (4) Hide

• Early Career Research Award: Parker Scholar, Parker Institute for Cancer Immunotherapy, 2025-2027
• Symbiont Seed Grant, Gladstone-UCSF Institute of Genomic Immunology, 2025-2026
• 2024 Conquer Cancer Young Investigator Award, American Society of Clinical Oncology, 2024-2025
• Physician-Scientist Fellow, Chan Zuckerberg Biohub - San Francisco, 2023-2025

Education & Training

Show all (6) Hide

• Medical Oncology Fellowship University of California San Francisco, San Francisco, California 06/2025
• Internal Medicine Residency Mount Sinai Hospital 06/2022
• Postdoctoral Cancer Research Training Award Fellow National Cancer Institute 06/2019
• MD Medicine University of Maryland School of Medicine 05/2017
• Post-baccalaureate Cancer Research Training Award Fellow National Cancer Institute 07/2013
• BS Biology Juniata College 05/2010

Publications (4)

Top publication keywords:
Receptors, Antigen, T-CellImmunotherapy, AdoptiveGenes, T-Cell ReceptorHLA-A2 AntigenRepressor ProteinsCD8 AntigensHuman papillomavirus 16Cytotoxicity, ImmunologicCarcinomaOncogene Proteins, ViralSialic Acid Binding Ig-like Lectin 2Cross ReactionsT-Cell Antigen Receptor SpecificityLeukemiaT-Lymphocyte Subsets

• CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.
  Science advances 2025 Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, Rae Z, Achar SR, Altan-Bonnet G, Zhang L, Wu X, Meyer TJ, Kelly MC, Taylor N, Hinrichs CS, Ishii K
• Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
  JCI insight 2018 Jin BY, Campbell TE, Draper LM, Stevanovic S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS
• Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Draper LM, Kwong ML, Gros A, Stevanovic S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS
• Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS